Login to Your Account



Angion advances BB3 with phase III in kidney transplant recipients

By Michael Fitzhugh
Staff Writer

Thursday, May 14, 2015
Angion Biomedica Corp. plans to soon begin enrolling a phase III study of BB3, an organ-protecting regenerative treatment it is testing in kidney transplant recipients with delayed graft function (DGF), a situation in which the organ fails to function properly, pushing patients onto dialysis after surgery.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription